Pruritus

Phase 2 trial results found lutikizumab was efficacious in treating hidradenitis suppurativa in patients who had previously failed anti-tumor necrosis factor therapy, AbbVie announced in a press release.

Using stabilized, super-oxidized hypochlorous acid during and after hair restoration surgery may assist in the healing process, according to a study.

SAN DIEGO — First-line treatment with ruxolitinib led to “clinically meaningful” positive results versus best available therapy in patients with high-risk polycythemia vera, according to data presented at ASH Annual Meeting.

The top 10 most viewed YouTube videos about topical corticosteroid withdrawal reflect poor reliability and accuracy, according to a study.

BOSTON — After 52 weeks, elafibranor achieved biochemical response and improved symptoms of pruritus in patients with primary biliary cholangitis, according to late-breaking data presented at The Liver Meeting.

Long-term trial results showed efficacy of rademikibart in Chinese patients with moderate to severe atopic dermatitis, Connect Biopharma announced in a press release.

BOSTON — In a Healio video exclusive, Pam Vig, PhD, reports late-breaking data that show Livmarli improved liver health and maintained symptom response over 2 years among pediatric patients with progressive familial cholestasis.

International Primary Biliary Cholangitis Day, celebrated on September 10, aspires to raise awareness of the challenges that patients with this rare liver disease face and how their stories can help advance diagnosis, treatment and care.

Seladelpar reduced serum alkaline phosphatase and bilirubin at 12 months in more than 60% of patients with primary biliary cholangitis compared with 20% of placebo-treated patients, according to manufacturer, CymaBay Therapeutics.

Moderate to severe pruritus remains a chronic problem in patients on maintenance hemodialysis that can reduce overall quality of life, according to recently published data.